---

BENIGN PROSTATIC HYPERPLASIA — Complete Content for 100 Slides

---

SECTION 1: INTRODUCTION & OVERVIEW (Slides 1–5)

• Benign Prostatic Hyperplasia (BPH)
• A comprehensive review: Pathology, Diagnosis & Management
• Sources: Smith & Tanagho's General Urology 19e; Campbell Walsh Wein Urology

• BPH = non-malignant enlargement of the prostate gland due to hyperplasia of stromal and epithelial cells
• Correctly termed hyperplasia (increased cell number), NOT hypertrophy (increased cell size)
• Develops in the transition zone of the prostate
• Leads to Lower Urinary Tract Symptoms (LUTS) via bladder outlet obstruction (BOO)
• Campbell Walsh Wein: "BPH is characterized by an increased number of epithelial and stromal cells in the periurethral area"

• Most common benign tumor in men; incidence is age-related
• Histologic BPH prevalence:
  • 20% in men aged 41–50 years
  • 50% in men aged 51–60 years
  • Up to 90% in men >80 years
• Clinical symptoms:
  • ~25% of men report obstructive symptoms at age 55
  • ~50% at age 75 report decreased force and caliber of stream
• Smith & Tanagho's, p.607

• Age (strongest risk factor)
• Genetics: ~50% of men <60 years who undergo surgery may have a heritable form
  • Most likely autosomal dominant trait
  • First-degree male relatives carry ~4-fold increased relative risk
• Race: higher in African Americans, lower in Asians
• Metabolic syndrome, obesity, diabetes mellitus
• Sedentary lifestyle
• Intact hypothalamic-pituitary-gonadal axis required (castrated men do not develop BPH)

• Second most costly surgical procedure on Medicare list (after cataract surgery)
• TURP peak: 258,000 procedures in 1987 in the US
• BPH accounts for significant healthcare burden globally
• Progressive disease: impacts urinary flow, quality of life, sexual function, and bladder/kidney health

---

SECTION 2: ANATOMY & ZONES OF THE PROSTATE (Slides 6–10)

• Normal prostate weight: ~20 g in young adult men
• Location: inferior to bladder, superior to urogenital diaphragm, surrounds prostatic urethra
• Divided into zones by McNeal:
  1. Peripheral zone (70%) — most prostate cancers arise here
  2. Transition zone (5–10%) — site of BPH
  3. Central zone (25%)
  4. Anterior fibromuscular stroma

• BPH develops exclusively in the transition zone
• As transition zone nodules enlarge → compress outer (peripheral) zone → formation of "surgical capsule"
• Surgical capsule separates transition zone from peripheral zone
• Serves as surgical plane for:
  • Open simple prostatectomy enucleation
  • Holmium laser enucleation of the prostate (HoLEP)
• Smith & Tanagho's, p.607: "BPH nodules in the transition zone compress the outer zones, resulting in the formation of a so-called surgical capsule"

• Clinically described in lobes (relevant to surgery):
  • Right and left lateral lobes
  • Median (middle) lobe — protrudes into bladder neck → "ball-valve" obstruction
  • Anterior lobe
  • Posterior lobe
• Median lobe enlargement = major cause of obstructive symptoms

• Prostate is traversed by prostatic urethra (~3 cm)
• Verumontanum (seminal colliculus): landmark for TURP — resection must remain proximal
• BPH narrows prostatic urethra → increased outlet resistance

• T2 MRI: Peripheral zone = high signal (bright crescent posteriorly)
• BPH: marked enlargement of central/transition zone; peripheral zone compressed
• Clinical distinction from prostate cancer important on multiparametric MRI (mpMRI)

---

SECTION 3: ETIOLOGY & PATHOGENESIS (Slides 11–18)

• BPH etiology is multifactorial and endocrine-controlled
• Key factors:
  • Androgens
  • Estrogens
  • Stromal-epithelial interactions
  • Growth factors
  • Neurotransmitters (especially α-adrenergic pathways)
• Campbell Walsh Wein: "The precise molecular etiology is uncertain... may be caused by epithelial and stromal proliferation or impaired programmed cell death"

• Castration → regression of established BPH + improvement in urinary symptoms
• Testosterone (especially DHT — dihydrotestosterone) is the active androgen
• DHT produced by 5α-reductase (type 2) in prostatic stromal cells
• DHT binds androgen receptor (AR) → stimulates cell growth
• Androgen deprivation → prostate volume reduction of ~20–30%
• Basis for 5α-reductase inhibitor therapy

• Positive correlation between free testosterone AND estrogen levels with BPH volume
• Aging → increased estrogen:testosterone ratio
• Estrogen may induce AR expression → sensitizes prostate to testosterone
• Estrogens act through stromal and epithelial estrogen receptors
• Campbell Walsh Wein: "Estrogens acting through stromal and epithelial estrogen receptors may contribute, in part, to diseases of the prostate"

• BPH = imbalance between cell proliferation and cell death
• NOT primarily an active proliferative process
• Key mechanism: impaired apoptosis (programmed cell death)
• Increased expression of anti-apoptotic genes (e.g., bcl-2)
• Androgens actively inhibit cell death
• α-adrenergic pathways may balance cell death and proliferation

• "Embryonic reawakening" hypothesis: stromal cells re-express fetal inductive potential
• New epithelial gland formation normally seen only in fetal development
• Branching morphogenesis regulated by stromal-epithelial interactions
• Testosterone acts through stromal androgen receptor to induce glandular regeneration
• Growth factors implicated: FGF, EGF, TGF-β, IGF

• BPH may be viewed as a stem cell disease (Isaacs, 2008)
• Multipotent basal stem cells in the proximal niche are responsible for replenishing apoptotic luminal epithelia
• Both basal and luminal stem cells capable of contributing to prostate regrowth
• Campbell Walsh Wein: "In the adult human prostate, quantitative clonal mapping revealed that multipotent basal stem cells in the proximal niche are mainly responsible for replenishing the loss of apoptotic luminal epithelia"

• BPH nodules composed of:
  • Stroma: varying amounts of collagen and smooth muscle
  • Epithelium: glandular elements
• Differential composition explains differential response to therapy:
  • Significant smooth muscle → better response to alpha-blockers
  • Predominantly epithelium → better response to 5α-reductase inhibitors
  • Predominantly collagen → may NOT respond to either
• Smith & Tanagho's, p.607

• Chronic prostatic inflammation increasingly recognized as a driver of BPH
• Elevated interleukins (IL-8, IL-17) and inflammatory cytokines
• Activated T-lymphocytes and macrophages in BPH tissue
• Potential therapeutic target: anti-inflammatory approaches
• Metabolic syndrome and insulin resistance promote prostatic inflammation

---

SECTION 4: PATHOPHYSIOLOGY & SYMPTOMS (Slides 19–26)

• Two components of obstruction:
  1. Mechanical obstruction: physical encroachment into urethral lumen and bladder neck → increased outlet resistance
  2. Dynamic obstruction: smooth muscle contraction in prostate and bladder neck (mediated by α1-adrenoreceptors) → functional narrowing
• Dynamic component = target of alpha-blocker therapy
• Smith & Tanagho's: "Obstruction can be subdivided into mechanical and dynamic forms"

• Phase 1 — Irritability/Instability: detrusor hypertrophy, increased contractility, OAB
• Phase 2 — Compensation: trabeculation, sacculation, diverticula formation
• Phase 3 — Decompensation: detrusor failure, large PVR, overflow incontinence
• Bladder wall changes: trabeculation (interlacing muscle bundles), cellules, diverticula
• Long-term obstruction → irreversible detrusor damage

• Storage symptoms often more bothersome than voiding symptoms

• International Prostate Symptom Score (IPSS) = 7 questions + 1 QoL question
• Each question scored 0–5; total 0–35
  • Mild: 0–7
  • Moderate: 8–19
  • Severe: 20–35
• QoL question: "If you were to spend the rest of your life with your urinary condition the way it is now, how would you feel?" (0–6)
• Gold standard for symptom assessment and treatment monitoring

• Variable and not always progressive
• ~1/3 improve, ~1/3 stable, ~1/3 worsen over time
• Key outcomes monitored (Campbell Table 144.8):
  • Symptom scores (IPSS)
  • Peak flow rate (Qmax)
  • Post-void residual (PVR)
  • Prostate volume
  • Serum PSA
• Complications: AUR, UTI, bladder stones, hydronephrosis, renal insufficiency

• Sudden inability to void despite a full bladder
• Annual risk: ~1–2% for men with moderate-to-severe LUTS
• Risk increases with:
  • IPSS ≥ 8
  • Qmax < 12 mL/s
  • Prostate volume > 30 mL
  • PSA > 1.4 ng/mL
• AUR is a definitive indication for surgical intervention
• Management: Foley catheterization → trial without catheter (TWOC) after 48–72 hours + alpha-blocker

1. Acute/chronic urinary retention
2. Urinary tract infections (recurrent)
3. Bladder calculi
4. Gross hematuria
5. Bladder diverticula
6. Detrusor overactivity and OAB
7. Detrusor underactivity
8. Hydroureteronephrosis
9. Renal insufficiency/failure (obstructive uropathy)
10. Hernia formation (straining)

• PSA correlates with prostate volume
• Serum PSA can be used to predict prostate volume (Roehrborn, 1999)
• PSA-based volume prediction stratified by age
• Importance: guides choice of 5ARI therapy vs. watchful waiting
• PSA >1.4 ng/mL associated with higher risk of AUR and need for surgery

---

SECTION 5: DIAGNOSIS & EVALUATION (Slides 27–35)

• History and physical examination
• IPSS/AUA symptom score
• Urinalysis ± urine culture
• Serum PSA
• Digital rectal examination (DRE)
• Uroflowmetry
• Post-void residual (PVR) — ultrasound
• Optional: imaging (TRUS/MRI), cystoscopy, urodynamics

• Onset, duration, progression of symptoms
• IPSS questionnaire
• Previous urologic history (UTIs, calculi, stricture, trauma, surgery)
• Medical history: diabetes, neurological disease, cardiac conditions
• Medications: anticholinergics, sympathomimetics, diuretics, opioids
• Sexual function — baseline erectile and ejaculatory function

• Assess prostate: size, consistency, symmetry, nodules, tenderness
• Normal prostate: rubbery, smooth, ~20 g
• BPH: enlarged, smooth, firm, non-tender, no nodules
• Hard/irregular nodule → suspect carcinoma → biopsy
• DRE often underestimates prostate volume (compared to TRUS/MRI)

• Rule out: UTI, hematuria, glucosuria (diabetes)
• Microscopic hematuria → cystoscopy + upper tract imaging to rule out malignancy
• Proteinuria → assess renal function

• Not a BPH-specific test, but:
  • Correlates with prostate volume
  • Predicts risk of AUR and need for surgery
  • Important to rule out prostate cancer
• Elevations also seen in: prostatitis, catheterization, DRE, prostate biopsy
• PSA density (PSA/prostate volume): >0.15 ng/mL/cc raises suspicion for cancer

• Non-invasive measurement of urine flow
• Key parameters:
  • Qmax (peak flow rate): normal >15 mL/s; BPH often <10 mL/s
  • Average flow rate
  • Voided volume (minimum 150 mL for reliable result)
  • Flow pattern (bell curve vs. plateaued = obstructed)
• Useful for baseline and monitoring treatment response

• Measured by bladder ultrasound after voiding
• Normal: <50 mL
• BPH: often 100–300 mL or more
• Significant PVR: >200 mL (risk for UTI, bladder dysfunction)
• Large PVR (>300 mL) → indication for more aggressive treatment

• Gold standard for prostate volume measurement
• Also detects: hypoechoic lesions suspicious for cancer
• Can guide prostate biopsy
• Formula: volume = 0.523 × length × width × height (ellipsoid formula)

• Gold standard to distinguish BOO from detrusor underactivity
• Indications: suspected neurogenic bladder, young patients, inconclusive uroflowmetry, prior to surgery
• Bladder outlet obstruction index (BOOI):
  • BOOI = Pdet.Qmax − 2(Qmax)
  • BOOI >40 = obstructed; 20–40 = equivocal; <20 = unobstructed
• Not routinely required for straightforward BPH

---

SECTION 6: MEDICAL MANAGEMENT (Slides 36–52)

• Options:
  1. Watchful waiting (active surveillance)
  2. Medical therapy
  3. Minimally invasive surgical therapies (MISTs)
  4. Conventional surgery
• Choice depends on: symptom severity (IPSS), bother, Qmax, PVR, prostate volume, PSA, complications

• Appropriate for: mild IPSS (0–7) or moderate IPSS without significant bother
• No risk of complications (infection, renal failure, AUR) required
• Patient education: voiding habits, fluid intake, avoid caffeine/alcohol/anticholinergics
• Annual reassessment: IPSS, Qmax, DRE, PSA
• ~40% of men with mild-moderate symptoms remain stable over 5 years

• Mechanism: block α1-adrenoceptors in prostate/bladder neck smooth muscle → relax smooth muscle → relieve dynamic obstruction
• Three subtypes of α1-receptor: α1a (dominant in prostate), α1b (vasculature), α1d (bladder/spinal cord)
• Drugs (all once-daily):
  • Terazosin (non-selective)
  • Doxazosin (non-selective)
  • Tamsulosin (α1a selective — fewer cardiovascular side effects)
  • Alfuzosin (uroselective)
  • Silodosin (highly α1a selective)
• Onset of action: days to weeks
• Side effects: orthostatic hypotension (especially non-selective), dizziness, retrograde ejaculation (silodosin, tamsulosin), intraoperative floppy iris syndrome (IFIS) in cataract surgery
• 2024 Network Meta-analysis (PMID 38750153): tamsulosin ranked most efficacious overall with favorable safety profile

• Mechanism: inhibit 5α-reductase → reduce DHT → prostate volume reduction (20–30%)
• Two agents:
  • Finasteride (type 2 5AR inhibitor)
  • Dutasteride (dual type 1 + type 2 inhibitor — more complete DHT suppression)
• Onset: weeks to months; maximum effect at 6–12 months
• Indications: prostate volume >30–40 mL or PSA >1.4 ng/mL
• Benefits: reduce risk of AUR by ~57%, reduce need for surgery by ~55% (PLESS, MTOPS trials)
• Side effects: decreased libido, erectile dysfunction, ejaculatory disorders, gynecomastia, decreased PSA by ~50% (must double PSA value for interpretation)
• Best suited: large prostate, elevated PSA

• MTOPS trial: combination > either monotherapy in preventing progression
• CombAT trial: dutasteride + tamsulosin superior to monotherapy at 4 years
• Combination reduces AUR risk by 67% vs. placebo
• Reduces need for BPH-related surgery by 64% vs. placebo
• Recommended for: moderate-severe LUTS + enlarged prostate (>30–40 mL) + elevated PSA

• Detrusor overactivity/OAB symptoms often co-exist with BOO
• Mechanism: block M2/M3 muscarinic receptors → reduce involuntary detrusor contractions → increase bladder capacity
• Drugs (Campbell Walsh Wein Table 145.12):
  • Darifenacin ER (7.5–15 mg/day)
  • Solifenacin (5–10 mg/day)
  • Tolterodine ER (4 mg/day)
  • Oxybutynin ER, Fesoterodine ER, Trospium
• Caution in BPH: risk of AUR (use when PVR <200 mL)
• Act mainly on bladder sensory pathways (not purely motor)

• Mirabegron: first beta-3 agonist approved for OAB
• Mechanism: stimulates β3-receptors in detrusor → relaxation during filling → increased bladder capacity
• Dose: 25–50 mg/day
• No significant effect on bladder outlet
• Advantage over antimuscarinics: no dry mouth, no AUR risk, better tolerated in elderly
• Combination with tamsulosin (SYMPHONY study): superior symptom relief vs. monotherapy
• Increasingly preferred in BPH/OAB overlap

• Tadalafil 5 mg once daily: FDA-approved for BPH/LUTS (also erectile dysfunction)
• Mechanism: inhibit phosphodiesterase-5 → increased cGMP → smooth muscle relaxation in prostate, bladder neck, and urethra
• Significant improvement in IPSS and erectile function simultaneously
• Does NOT significantly improve Qmax (unlike alpha-blockers)
• Useful in men with BPH + erectile dysfunction
• Side effects: headache, flushing, dyspepsia; avoid with nitrates

• Widely used; limited evidence from high-quality RCTs
• Common agents:
  • Saw palmetto (Serenoa repens): multiple RCTs show no superiority over placebo
  • Beta-sitosterol: modest improvement in IPSS
  • Pygeum africanum: anti-inflammatory effects
  • Stinging nettle (Urtica dioica)
• Not recommended as first-line by AUA/EAU guidelines
• Patient preference and cultural factors may drive use

• Naftopidil (α1d-selective blocker): greater effect on storage symptoms, available in Asia
• Vibegron (beta-3 agonist): newer option for OAB/storage symptoms
• Elagolix (GnRH antagonist): investigated for prostate volume reduction
• Combination alpha-blocker + beta-3 agonist (mirabegron + tamsulosin): increasingly used
• Anti-inflammatory targets (COX inhibitors, interleukin modulation): under investigation

---

SECTION 7: MINIMALLY INVASIVE SURGICAL THERAPIES (MISTs) (Slides 47–62)

• Bridging the gap between medical therapy and conventional surgery
• Target patients: inadequate response to medications, unfit for major surgery, wish to preserve sexual function
• Key advantages: office-based or outpatient, preserve ejaculatory function, faster recovery, lower morbidity
• 2023 EAU Network Meta-analysis (PMID 36964042): reviewed 22 MISTs vs. TURP in 9 domains

• Approved by FDA in 2013
• Mechanism: permanent implants (UroLift sutures) compress lateral lobes of prostate → open urethral lumen mechanically without heat/ablation
• Procedure: cystoscope-guided, local anesthesia, 20–30 minutes
• Eligibility: prostate 30–80 mL, no prominent median lobe
• Outcomes:
  • IPSS improvement: ~47%
  • Qmax improvement: ~44%
  • 5-year durability: retreatment rate ~13%
• Key advantage: preserves ejaculatory function (no retrograde ejaculation)
• Side effects: dysuria, hematuria (transient), implant migration (rare)

• FDA approved 2015
• Mechanism: convective water vapor (steam) at 103°C injected into transition zone → thermal ablation of hyperplastic tissue → natural resorption over weeks
• Procedure: office-based, local/topical anesthesia, <10 minutes
• Eligibility: prostate 30–80 mL, including median lobe
• Outcomes:
  • IPSS: ~50% improvement sustained at 4 years
  • Qmax: ~50% improvement
  • Retreatment rate: ~4.4% at 4 years
• Advantage: treats median lobe; generally preserves erectile and ejaculatory function
• Side effects: dysuria, frequency, temporary catheterization (5–7 days post-procedure)

• FDA approved 2017
• Mechanism: image-guided (transrectal ultrasound) robotic waterjet ablation of prostatic tissue at high velocity (saline) — removes tissue precisely without thermal energy
• Procedure: general/spinal anesthesia, operating room setting; TRUS + cystoscopy guidance
• Eligibility: prostate 30–150 mL; effective for large/complex anatomy
• Outcomes:
  • AQUA II RCT vs. TURP: non-inferior IPSS improvement
  • WATER II study (prostate 80–150 mL): significant improvement in IPSS and Qmax
  • Retrograde ejaculation rate: only ~10% vs. ~65% with TURP
• Side effects: post-procedure bleeding requiring balloon tamponade (~10%)
• 2023–2024 evidence: increasingly positioned as preferred for sexual function preservation

• Mechanism: microwave energy delivered via intraurethral antenna → heat (45–70°C) → coagulative necrosis of periurethral prostate tissue
• Done under local anesthesia as outpatient procedure
• Requires post-procedure catheterization (5–7 days)
• IPSS improvement: 40–70%; Qmax improvement: 60–70%
• Durability: retreatment rate ~20% at 5 years (lower than TURP)
• Less commonly performed now due to superior alternatives
• Suitable for high-risk surgical patients

• Mechanism: radiofrequency energy via needles placed into prostate → focal coagulative necrosis
• Done under local anesthesia
• Similar outcomes to TUMT
• Less commonly used now; largely replaced by Rezūm/UroLift
• Low incidence of retrograde ejaculation and erectile dysfunction

• Interventional radiology procedure (not urologic surgery)
• Mechanism: selective catheterization of prostatic arteries → microsphere embolization → ischemic necrosis → prostate volume reduction
• Access: transfemoral or transradial; 4–5Fr catheter; microcatheter 2.5Fr or smaller
• Smith & Tanagho's, p.121: "A 10–15-point reduction in AUA-SI scores can be achieved weeks to months after the procedure"
• Large prostates (>90 g): volume reduction ~33%, AUA-SI reduction >80% at 3 months
• PAE vs. TURP: similar symptomatic improvement; TURP superior for Qmax and PVR
• Patients with chronic indwelling catheters: ~100% successful TWOC at 2 weeks
• 3–5 year durability: 70% maintain symptomatic improvement (Pisco, 2016)
• 2024 Meta-analysis (PMID 38281906): PAE comparable to surgical/MIST procedures for symptomatic relief
• Advantage: no anesthesia risk, no retrograde ejaculation, treats very large prostates
• Side effects: post-embolization syndrome (fever, pelvic pain), non-target embolization

• FDA approved 2020
• Mechanism: nitinol device placed in prostatic urethra for 5–7 days → reshapes and widens prostatic urethra via pressure → permanent anatomical change
• Removed in office setting
• No thermal energy, no permanent implant
• IPSS improvement: ~47% at 12 months
• Key advantage: no catheter required post-procedure; preserves sexual function
• Suitable for prostate 25–75 mL without prominent median lobe

• Drug-coated balloon (paclitaxel) dilates and treats prostatic urethra
• Dual mechanism: mechanical dilation + antiproliferative drug delivery
• FDA approved 2023 for prostates 20–150 mL
• Early results: IPSS improvement ~45%, Qmax improvement ~70%
• Advantage: preserves ejaculatory function, office-based

---

SECTION 8: CONVENTIONAL SURGICAL MANAGEMENT (Slides 57–75)

• Absolute indications:
  • Refractory AUR (failed TWOC)
  • Recurrent UTIs due to BPH
  • Bladder stones secondary to BPH
  • Gross hematuria from prostate
  • Renal insufficiency due to BOO
  • Large bladder diverticula
• Relative indications:
  • Moderate-severe LUTS refractory to medical therapy
  • High PVR (>300 mL)
  • Significant symptom bother
  • Patient preference

• Gold standard for surgical treatment of BPH for decades
• Most commonly performed prostate surgery worldwide
• Technique:
  • Resectoscope inserted via urethra
  • Electrical loop resects prostatic tissue in chips
  • Continuous irrigation maintains visibility
  • Resection from bladder neck to verumontanum
  • Foley catheter × 24–48 hours post-op
• Prostate size: optimal for <80–100 mL

• IPSS improvement: 70–90%
• Qmax improvement: 100–200%
• 5-year durability: retreat rate ~15%
• 10-year durability: retreat rate ~20–25%
• 30-day mortality rate: decreased from 1.2% (1984) to 0.77% (1990); currently <0.25%
• 2024 Systematic Review (PMID 39547977): "TURP demonstrates sustained efficacy over 20 years with acceptable morbidity"

• TUR syndrome (monopolar TURP):
  • Absorption of hypotonic irrigant (glycine) → dilutional hyponatremia → cerebral edema
  • Symptoms: nausea, confusion, visual disturbance, hypertension, bradycardia
  • Risk: longer resection time, deep venous sinuses opened
  • Management: furosemide, 3% hypertonic saline (if Na <120)
  • Incidence: 0.1–0.5% with modern technique
• Retrograde ejaculation: 65–90%
• Erectile dysfunction: 5–10%
• Bleeding requiring transfusion: 2–5%
• Urethral stricture: 2–9%
• Bladder neck contracture: 2–4%
• Incontinence: <1% (transient)

• Uses saline (isotonic) as irrigant → no TUR syndrome
• Plasma vaporization of tissue between two electrodes on same resectoscope
• Otherwise similar technique to monopolar TURP
• Equivalent efficacy to monopolar TURP
• Reduced hyponatremia risk, reduced blood loss
• Now preferred over monopolar TURP in most centers

• Considered by many the new standard of care for BPH regardless of prostate size
• Mechanism: holmium:YAG laser (2140 nm) used to enucleate entire transition zone along surgical capsule plane → tissue morcellated and retrieved
• No size limitation — effective for prostates >200 g
• Outcomes:
  • IPSS improvement: equivalent to TURP/open prostatectomy
  • Qmax improvement: superior to TURP at long-term follow-up
  • Retreatment rate: ~1–2% at 10 years (lowest of any BPH surgery)
  • Durability: best long-term outcomes of any BPH surgery
• 2023 Meta-analysis (PMID 37561537): "HoLEP associated with significantly better IPSS improvement, Qmax, and lower retreatment rates vs. TURP"
• Complications: retrograde ejaculation ~75%, temporary incontinence ~5–15%, learning curve

• Thulium:YAG laser (2013 nm) or Thulium fiber laser (TFL, 1940 nm)
• Similar enucleation technique to HoLEP
• TFL: continuous wave energy → more efficient tissue cutting with less thermal spread
• Comparable outcomes to HoLEP
• Some evidence of lower intraoperative bleeding
• Increasingly adopted as alternative to HoLEP

• KTP/LBO laser (532 nm, green wavelength) — absorbed by hemoglobin → vaporization of prostatic tissue
• 180 W system (XPS GreenLight)
• Advantages: minimal bleeding, outpatient, suitable for anticoagulated patients
• Outcomes:
  • IPSS and Qmax improvement comparable to TURP
  • Lower transfusion rate, shorter catheter time
  • Higher retreatment rate than HoLEP at long-term follow-up
• Retrograde ejaculation: 50–60%
• Limitation: no tissue for histology

• 980 nm / 1470 nm diode lasers: vaporization and coagulation
• Thulium fiber laser (TFL): most recent advancement; low threshold for photoablation
• Emerging evidence for TFL enucleation comparable to HoLEP with potentially fewer complications
• MOSES technology (HoLEP): modified holmium pulse — more efficient energy delivery, less tissue retropulsion

• Indicated for very large prostates (>100–150 mL) where endoscopic surgery is difficult
• Two approaches:
  1. Millin (retropubic) prostatectomy: incision into anterior prostatic capsule → digital enucleation of adenoma
  2. Freyer (suprapubic/transvesical) prostatectomy: bladder opened → enucleation through bladder neck
• Complete removal of transition zone adenoma
• Outcomes: excellent long-term results, lowest retreatment rate among open approaches
• Morbidity: blood loss, longer hospitalization, wound complications
• Largely replaced by HoLEP for large glands in expert centers

• Minimally invasive version of open simple prostatectomy
• Robot-assisted laparoscopic approach (da Vinci system)
• Technique: retropubic or transvesical robot-assisted enucleation
• Comparable functional outcomes to open prostatectomy
• Advantages: less blood loss, shorter hospital stay, better visualization
• Increasingly adopted for large prostates (>80–100 mL) where HoLEP expertise unavailable
• 2024 data: RSP outcomes comparable to HoLEP for glands >100 mL

• Laparoscopic alternative to open prostatectomy
• Less commonly performed than robotic approach
• Similar outcomes to open; more technically demanding
• Retropubic or transvesical approach

• Prostate <80 mL: TURP (bipolar), GreenLight PVP, MISTs
• Prostate 80–150 mL: HoLEP, ThuLEP, Bipolar TURP, Robotic Simple Prostatectomy
• Prostate >150 mL: HoLEP (preferred), Open/Robotic Simple Prostatectomy, PAE
• Principle: HoLEP has no size limit and remains gold standard across all prostate volumes

• UroLume (permanent metallic stent): placed transurethrally, early FDA approval
• High complication rates (encrustation, migration, tissue ingrowth, pain) → largely abandoned
• Temporary stents (biodegradable, removable): used as bridge to definitive surgery in high-risk patients
• Not routinely recommended in current guidelines

• Bladder neck contracture (BNC): occurs in 2–4% post-TURP
  • Management: urethrotomy, dilation, or revision TURP
• Urethral stricture: 2–9% post-TURP
  • Risk factors: catheter size, duration, resectoscope trauma
  • Management: optical urethrotomy, dilation, urethroplasty

• Anticoagulated patients: GreenLight PVP preferred (least bleeding); bipolar TURP if bridging
• Renal transplant patients: HoLEP/TURP safe ≥3 weeks post-transplant; avoid in first 2 weeks (risk of sepsis) — Campbell Walsh Wein, p.2590
• Neurogenic bladder + BPH: urodynamic assessment mandatory before surgery
• Urinary retention with large diverticulum: may need concomitant diverticulectomy
• Patients on dialysis/CRF: TURP safe; correct coagulopathy first

• Pre-op: urinalysis/culture (treat UTI), stop anticoagulants (bridge if needed), baseline renal function
• Anesthesia: spinal preferred for TURP (detects TUR syndrome early, patient awake); general acceptable for HoLEP/RSP
• Catheter: Foley 3-way 22Fr for TURP irrigation
• Irrigation fluid: saline for bipolar/laser; glycine for monopolar (avoid TUR syndrome)
• Post-op: early mobilization, remove catheter Day 1–2 (TURP), Day 1 (HoLEP/PVP)

• AUA/IPSS at 3 months, 12 months
• Uroflowmetry + PVR at 3 months
• PSA at 3 months (new baseline after removal of adenoma)
• Renal function if pre-op hydronephrosis
• Sexual function questionnaires (IIEF-5, MSHQ-EjD)

---

SECTION 9: RECENT ADVANCES IN BPH TREATMENT (Slides 76–90)

• Paradigm shift: from purely ablative/resective to tissue-selective, function-preserving approaches
• Key themes:
  1. Office-based MISTs replacing operating room procedures
  2. Laser enucleation (HoLEP/ThuLEP) displacing TURP as gold standard
  3. Preservation of ejaculatory and erectile function
  4. Robotic and image-guided approaches for large glands
  5. Combination drug therapy optimization

• WATER III trial (ongoing): aquablation in complex anatomy, median lobe, very large prostates
• AI-guided robotic heat map: ensures precise surgeon-independent resection
• HYDROS robotic system: fully automated aquablation with no surgeon manual control during ablation
• Sexual function outcomes: 90% preservation of ejaculatory function at 3 years
• 2024 data: emerging as gold standard for sexual function–conscious patients

• Novel drug-coated balloon: paclitaxel prevents fibrosis/restenosis
• PINNACLE study: IPSS −49%, Qmax +107% at 12 months
• Longer durable results anticipated from antiproliferative mechanism
• Office-based, local anesthesia, no implant left behind

• FDA approved 2020; CE marked
• SENZA-1 trial: significant IPSS, Qmax, QoL improvement at 3 years
• Advantages: no thermal energy, no permanent implant, outpatient, sexual function preserved
• Now incorporated into AUA guidelines as an option for prostates 25–75 mL

• TFL (1940 nm): continuous-wave modality vs. pulsed holmium
• Lower energy threshold for tissue ablation → more precise cutting
• BIOLASE and IPG Photonics systems commercially available
• Studies show: equivalent outcomes to HoLEP with potentially less bleeding and shorter learning curve
• Growing adoption in Europe and Asia; increasing data 2022–2025

• Modulated Optimal Sequential Energy (MOSES)
• Modified holmium pulse shape: "prepulse + main pulse" → creates vapor bubble that channels laser energy directly to tissue
• Benefits: less tissue retropulsion, more efficient ablation, less irrigation use
• MOSES 2.0 (Lumenis): further optimized pulse modulation
• Clinical data: reduced operative time, improved hemostasis

• Early investigational use of robotic assistance for HoLEP
• Aims to reduce learning curve through haptic feedback and 3D magnification
• Currently in feasibility trials; not yet commercially available
• Potential to democratize HoLEP beyond high-volume expert centers

• ROPE registry (multi-center European data): PAE effective and durable at 5 years
• TRAJECTOIRE RCT (France): PAE vs. TURP — PAE non-inferior in IPSS at 1 year, TURP superior in Qmax
• 2024 Meta-analysis (PMID 38281906): PAE comparable to MISTs for subjective outcomes; TURP superior in objective measures
• AUA 2023 guidelines: PAE listed as an option for appropriate candidates (shared decision-making)
• Increasing role in: very large prostates, high operative risk, patient preference to avoid anesthesia

• Concept of targeted focal ablation of hyperplastic tissue
• High-intensity focused ultrasound (HIFU) for BPH: limited data, investigational
• MRI-guided focused ultrasound: thermal ablation under MRI guidance, no incision
• Photodynamic therapy (PDT): investigational
• Gene therapy: targeting growth factor pathways — early laboratory phase

• Silodosin + mirabegron combination: increasingly used
• Cernilton (rye pollen extract): some RCT data for symptom relief
• Naftopidil: highly α1d selective; better for storage symptoms; used in Japan/Asia
• Testosterone replacement: paradoxically does NOT worsen BPH in hypogonadal men on physiologic replacement
• Investigational: RhoA/ROCK inhibitors, purinergic receptor modulators, growth factor antagonists (TGF-β, FGF)

• Post-MIST (e.g., Rezūm, UroLift): alpha-blockers continued for 3–4 weeks during tissue remodeling
• 5ARIs post-MIST: reduce retreatment rates in men with large prostates
• Mirabegron + MIST: for residual storage symptoms post-procedure
• Evidence supports multimodal approach in men with mixed LUTS

• Metabolic syndrome (obesity, diabetes, hypertension, dyslipidemia) strongly associated with BPH
• Insulin resistance → elevated IGF-1 → prostatic growth
• Adipokine dysregulation → prostatic inflammation
• Physical activity and weight loss: shown to reduce LUTS severity and prostate volume
• Bariatric surgery → significant improvement in LUTS (emerging data)
• Implications: lifestyle modification as adjunct to BPH management

• BPH/LUTS strongly associated with sexual dysfunction (ejaculatory more than erectile)
• Alpha-blockers → retrograde ejaculation (especially silodosin, tamsulosin)
• 5ARIs → decreased libido, ED, ejaculatory dysfunction (reversible in most)
• HoLEP, TURP → ~75–90% retrograde ejaculation
• Function-preserving surgeries (UroLift, Rezūm, AquaBeam, PAE) → maintain antegrade ejaculation
• Counseling essential: shared decision-making regarding procedure choice and sexual outcomes

• Watchful waiting: mild IPSS or bothersome-absent moderate IPSS, normal Qmax, no complications
• Medical therapy:
  • Alpha-blocker alone: first-line for moderate-severe LUTS
  • 5ARI: prostate >30–40 mL or PSA >1.4
  • Combination: moderate-severe LUTS + enlarged prostate
  • Beta-3 agonist/antimuscarinic: predominant storage symptoms
  • PDE5 inhibitor: LUTS + ED
• Surgery: absolute indications (AUR, recurrent UTI, hematuria, renal impairment, stones) or medical failure
• MISTs: intermediate option; patient counseling regarding durability and sexual function
• HoLEP: recommended for all prostate sizes in experienced centers

• PMID 36964042 (Eur Urol, 2023): Among 22 treatments, TURP and HoLEP had best objective outcomes; MISTs preferred for sexual function preservation
• PMID 38600763 (BJU Int, 2024): Re-intervention rates: HoLEP lowest → ThuLEP → bipolar TURP → GreenLight PVP → UroLift → Rezūm
• PMID 37561537 (J Int Med Res, 2023): HoLEP significantly superior to TURP in Qmax, IPSS, blood loss, catheter time; comparable complications
• PMID 38750153 (Sci Rep, 2024): Tamsulosin most efficacious alpha-blocker with best tolerability

---

SECTION 10: SPECIAL TOPICS & CLINICAL SCENARIOS (Slides 91–100)

• ~50% may have heritable form (autosomal dominant)
• Aggressive natural history; higher likelihood of progression
• 5ARI therapy preferred to arrest growth
• Sexual function preservation paramount → MISTs preferred over TURP/HoLEP
• Comprehensive genetic counseling if family history

• BPH and prostate cancer can coexist
• PSA interpretation critical: PSA >10 → biopsy even if BPH suspected
• Avoid treating BPH medically/surgically if cancer not excluded
• TURP chips → 10% may reveal incidental prostate cancer (T1a/T1b staging)
• T1a: <5% chips involved, Gleason ≤6 → monitoring acceptable
• T1b: >5% chips or high grade → staging and treatment

• Spinal cord injury, multiple sclerosis, Parkinson disease, diabetes
• Detrusor-sphincter dyssynergia may mask obstructive symptoms
• Urodynamics mandatory before surgical intervention
• Medical: alpha-blockers + antimuscarinics most useful
• TURP may worsen incontinence if sphincter compromised

• Large diverticula (>5 cm): risk of urinary stasis, infection, stones, malignancy
• Persistent diverticula after BOO relief: may require diverticulectomy
• Small (<2 cm) diverticula: often resolve with BOO relief
• Open/robotic approach: combined prostatectomy + diverticulectomy

• Estimated 3-year incidence: 9.7% in renal transplant population
• Anuric/oliguric state makes diagnosis difficult
• Pre-transplant: alpha-blockers prophylactically; TURP/HoLEP if severe BPH
• Post-transplant: avoid TURP in first 2 weeks (sepsis, graft loss risk)
• Safe after 3 weeks; avoid TURP with ureteral stent in situ
• Campbell Walsh Wein, p.2590

1. Foley catheter insertion
2. Alpha-blocker (tamsulosin 0.4 mg) for 48–72 hours
3. Trial without catheter (TWOC)
4. Successful TWOC → continue alpha-blocker + 5ARI (if large prostate)
5. Failed TWOC (2nd attempt) → surgical referral
6. Unfit for surgery → clean intermittent catheterization (CIC) or permanent suprapubic catheter

• Gross hematuria from BPH due to hypervascular gland
• Must exclude: bladder cancer, upper tract tumor, stone, infection
• Investigations: urine cytology, cystoscopy, CT urogram
• 5ARIs reduce hematuria from BPH (reduce vascularity)
• Persistent/severe hematuria → indication for surgery (TURP/HoLEP)
• Finasteride: reduces recurrence of BPH-related hematuria (RCT evidence)

• BPH management is largely elective (except absolute surgical indications)
• Patient values and preferences central to treatment choice
• Key discussion points:
  • Symptom bother vs. side effects of treatment
  • Sexual function (ejaculation priority → UroLift/Rezūm/AquaBeam/PAE)
  • Desire for definitive long-term solution → HoLEP
  • Comorbidities and anesthesia risk → office-based MISTs
  • Anticoagulation → GreenLight PVP
• Use of decision aids and visual aids recommended

• BPH is a progressive, age-related disease affecting >50% of men >60 years
• IPSS/AUA score guides severity assessment and treatment monitoring
• Medical therapy: alpha-blockers for rapid relief; 5ARIs for volume reduction and long-term prevention; combination for high-risk progression
• MISTs are transforming BPH management — office-based, sexual-function preserving
• HoLEP is the emerging global standard for surgical BPH management — no size limit, lowest retreatment rate, most durable
• AquaBeam and Rezūm represent the future of function-preserving surgical intervention
• Robotic simple prostatectomy expanding access for large glands
• PAE: viable minimally invasive IR option, especially for large glands/high-risk patients
• Shared decision-making, patient preference, and anatomy guide procedure selection
• Future: AI-guided surgery, focal therapies, novel molecular targets, lifestyle interventions

---

IMAGES TO INCLUDE (from Textbook & Medical Library)

1. Prostate MRI T2 — BPH vs. Normal vs. Cancer comparison — pmc_clinical_VQA_c78264686...
2. BPH — transition zone expansion with compressed peripheral zone — pmc_clinical_VQA_bc45e5...
3. BPH gross pathology — median lobe enlargement, ball-valve obstruction — Pathology_1760054...
4. PSA vs. prostate volume prediction chart — Campbell block80, line 299 (from textbook)
5. PAE angiogram — Smith & Tanagho's block1, lines 3585–3588
6. IPSS scoring table
7. Prostate zones diagram (McNeal)
8. TURP technique diagram
9. HoLEP enucleation diagram
10. Treatment algorithm flowchart (AUA 2023)

---

KEY REFERENCES

• Smith and Tanagho's General Urology, 19th Edition — Chapter 7 (Interventional Radiology), Chapter on BPH
• Campbell Walsh Wein Urology — Chapters 144, 145 (BPH: Natural History, Medical/Surgical Management)
• Chen F et al. J Int Med Res 2023 — HoLEP vs. TURP meta-analysis [PMID 37561537]
• Cornu JN et al. Eur Urol 2023 — Minimally invasive BPO treatments network meta-analysis [PMID 36964042]
• Shin BNH et al. BJU Int 2024 — Re-intervention rates of new surgical interventions [PMID 38600763]
• Altman R et al. BMC Urol 2024 — PAE vs. surgical/MIST meta-analysis [PMID 38281906]
• Yoosuf BT et al. Sci Rep 2024 — Alpha-blocker network meta-analysis [PMID 38750153]
• Porto JG et al. World J Urol 2024 — TURP 20-year systematic review [PMID 39547977]
• Abid A et al. Prostate 2024 — MISTs in geriatric population [PMID 38656693]

---

Definitions of LUTS — Storage, Voiding & Post-micturition Symptoms

---

STORAGE SYMPTOMS

---

VOIDING SYMPTOMS

---

POST-MICTURITION SYMPTOMS

---

Clinical Notes

• Storage symptoms are primarily driven by detrusor overactivity (OAB) or reduced bladder compliance — they respond to antimuscarinics/beta-3 agonists
• Voiding symptoms are primarily driven by bladder outlet obstruction (BOO) or detrusor underactivity — they respond to alpha-blockers, 5ARIs, or surgery
• Post-micturition symptoms reflect either urethral pooling (post-void dribble) or incomplete bladder emptying (large PVR) — the latter requires measurement and may indicate need for surgical decompression
• In BPH, voiding symptoms arise first, but storage symptoms (especially nocturia and urgency) are often the most bothersome to patients and most strongly impact quality of life
• The IPSS/AUA-SI captures 3 storage, 3 voiding, and 1 post-micturition symptom across its 7 questions